Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Company profile
Ticker
ATXI
Exchange
Website
CEO
Dr. Alexandra MacLean M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Restoration Robotics Inc, Restoration Robotics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Baergic Bio, Inc. ...
ATXI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
27 Sep 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
8-K
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
9 Aug 24
S-8
Registration of securities for employees
12 Jul 24
8-K
Departure of Directors or Certain Officers
26 Jun 24
8-K
Other Events
23 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
15 May 24
EFFECT
Notice of effectiveness
13 May 24
424B3
Prospectus supplement
10 May 24
Latest ownership filings
4
JAY D KRANZLER
1 Oct 24
4
LINDSAY A MD ROSENWALD
25 Sep 24
4
Neil Herskowitz
25 Sep 24
4
Curtis Gale Oltmans
25 Sep 24
4
Alexandra MacLean
25 Sep 24
4
JAY D KRANZLER
25 Sep 24
4
David Jin
25 Sep 24
4
Faith L. Charles
25 Sep 24
SC 13G/A
Davidow Robert L
2 May 24
SC 13D/A
Fortress Biotech, Inc.
17 Apr 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.92 mm | 4.92 mm | 4.92 mm | 4.92 mm | 4.92 mm | 4.92 mm |
Cash burn (monthly) | (no burn) | (no burn) | 941.00 k | 893.17 k | 751.00 k | 715.50 k |
Cash used (since last report) | n/a | n/a | 3.53 mm | 3.35 mm | 2.82 mm | 2.69 mm |
Cash remaining | n/a | n/a | 1.39 mm | 1.57 mm | 2.10 mm | 2.23 mm |
Runway (months of cash) | n/a | n/a | 1.5 | 1.8 | 2.8 | 3.1 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.11 mm |
Total shares | 4.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FBIO Fortress Biotech | 3.56 mm | $469.00 k |
CVI Investments | 251.01 k | $0.00 |
Intracoastal Capital | 216.79 k | $616.00 k |
InvaGen Pharmaceuticals | 10.00 | $0.00 |
Emfo | 8.00 | $28.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep 24 | Kranzler Jay D | COMMON STOCK, PAR VALUE $0.0001 | Buy | Acquire P | No | No | 2.5 | 497 | 1.24 k | 620 |
27 Sep 24 | Kranzler Jay D | COMMON STOCK, PAR VALUE $0.0001 | Buy | Acquire P | No | No | 2.4 | 3 | 7.20 | 123 |
23 Sep 24 | Faith L. Charles | Employee stock option Common Stock | Grant | Acquire A | No | No | 2.46 | 30,000 | 73.80 k | 30,000 |
23 Sep 24 | Kranzler Jay D | Employee stock option Common Stock | Grant | Acquire A | No | No | 2.46 | 30,000 | 73.80 k | 30,000 |
23 Sep 24 | David Jin | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 65,000 | 0.00 | 65,000 |
23 Sep 24 | Alexandra MacLean | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 170,000 | 0.00 | 170,000 |
Press releases
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
9 Oct 24
Avenue Therapeutics to Participate in Upcoming Investor Conferences
3 Sep 24
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
13 Aug 24
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
9 Aug 24